Cargando…

Brain Tumor Radiogenomic Classification of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation in Malignant Gliomas-Based Transfer Learning

Artificial Intelligence (AI) is the subject of a challenge and attention in the field of oncology and raises many promises for preventive diagnosis, but also fears, some of which are based on highly speculative visions for the classification and detection of tumors. A brain tumor that is malignant i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakly, Houneida, Said, Mourad, Seekins, Jayne, Guetari, Ramzi, Kraiem, Naoufel, Marzougui, Mehrez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126792/
https://www.ncbi.nlm.nih.gov/pubmed/37078100
http://dx.doi.org/10.1177/10732748231169149
_version_ 1785030336151814144
author Sakly, Houneida
Said, Mourad
Seekins, Jayne
Guetari, Ramzi
Kraiem, Naoufel
Marzougui, Mehrez
author_facet Sakly, Houneida
Said, Mourad
Seekins, Jayne
Guetari, Ramzi
Kraiem, Naoufel
Marzougui, Mehrez
author_sort Sakly, Houneida
collection PubMed
description Artificial Intelligence (AI) is the subject of a challenge and attention in the field of oncology and raises many promises for preventive diagnosis, but also fears, some of which are based on highly speculative visions for the classification and detection of tumors. A brain tumor that is malignant is a life-threatening disorder. Glioblastoma is the most prevalent kind of adult brain cancer and the 1 with the poorest prognosis, with a median survival time of less than a year. The presence of O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation, a particular genetic sequence seen in tumors, has been proven to be a positive prognostic indicator and a significant predictor of recurrence. This strong revival of interest in AI is modeled in particular to major technological advances which have significantly increased the performance of the predicted model for medical decision support. Establishing reliable forecasts remains a significant challenge for electronic health records (EHRs). By enhancing clinical practice, precision medicine promises to improve healthcare delivery. The goal is to produce improved prognosis, diagnosis, and therapy through evidence-based sub stratification of patients, transforming established clinical pathways to optimize care for each patient’s individual requirements. The abundance of today’s healthcare data, dubbed “big data,” provides great resources for new knowledge discovery, potentially advancing precision treatment. The latter necessitates multidisciplinary initiatives that will use the knowledge, skills, and medical data of newly established organizations with diverse backgrounds and expertise. The aim of this paper is to use magnetic resonance imaging (MRI) images to train and evaluate your model to detect the presence of MGMT promoter methylation in this competition to predict the genetic subtype of glioblastoma based transfer learning. Our objective is to emphasize the basic problems in the developing disciplines of radiomics and radiogenomics, as well as to illustrate the computational challenges from the perspective of big data analytics.
format Online
Article
Text
id pubmed-10126792
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-101267922023-04-26 Brain Tumor Radiogenomic Classification of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation in Malignant Gliomas-Based Transfer Learning Sakly, Houneida Said, Mourad Seekins, Jayne Guetari, Ramzi Kraiem, Naoufel Marzougui, Mehrez Cancer Control Review Artificial Intelligence (AI) is the subject of a challenge and attention in the field of oncology and raises many promises for preventive diagnosis, but also fears, some of which are based on highly speculative visions for the classification and detection of tumors. A brain tumor that is malignant is a life-threatening disorder. Glioblastoma is the most prevalent kind of adult brain cancer and the 1 with the poorest prognosis, with a median survival time of less than a year. The presence of O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation, a particular genetic sequence seen in tumors, has been proven to be a positive prognostic indicator and a significant predictor of recurrence. This strong revival of interest in AI is modeled in particular to major technological advances which have significantly increased the performance of the predicted model for medical decision support. Establishing reliable forecasts remains a significant challenge for electronic health records (EHRs). By enhancing clinical practice, precision medicine promises to improve healthcare delivery. The goal is to produce improved prognosis, diagnosis, and therapy through evidence-based sub stratification of patients, transforming established clinical pathways to optimize care for each patient’s individual requirements. The abundance of today’s healthcare data, dubbed “big data,” provides great resources for new knowledge discovery, potentially advancing precision treatment. The latter necessitates multidisciplinary initiatives that will use the knowledge, skills, and medical data of newly established organizations with diverse backgrounds and expertise. The aim of this paper is to use magnetic resonance imaging (MRI) images to train and evaluate your model to detect the presence of MGMT promoter methylation in this competition to predict the genetic subtype of glioblastoma based transfer learning. Our objective is to emphasize the basic problems in the developing disciplines of radiomics and radiogenomics, as well as to illustrate the computational challenges from the perspective of big data analytics. SAGE Publications 2023-04-19 /pmc/articles/PMC10126792/ /pubmed/37078100 http://dx.doi.org/10.1177/10732748231169149 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Sakly, Houneida
Said, Mourad
Seekins, Jayne
Guetari, Ramzi
Kraiem, Naoufel
Marzougui, Mehrez
Brain Tumor Radiogenomic Classification of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation in Malignant Gliomas-Based Transfer Learning
title Brain Tumor Radiogenomic Classification of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation in Malignant Gliomas-Based Transfer Learning
title_full Brain Tumor Radiogenomic Classification of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation in Malignant Gliomas-Based Transfer Learning
title_fullStr Brain Tumor Radiogenomic Classification of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation in Malignant Gliomas-Based Transfer Learning
title_full_unstemmed Brain Tumor Radiogenomic Classification of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation in Malignant Gliomas-Based Transfer Learning
title_short Brain Tumor Radiogenomic Classification of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation in Malignant Gliomas-Based Transfer Learning
title_sort brain tumor radiogenomic classification of o(6)-methylguanine-dna methyltransferase promoter methylation in malignant gliomas-based transfer learning
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126792/
https://www.ncbi.nlm.nih.gov/pubmed/37078100
http://dx.doi.org/10.1177/10732748231169149
work_keys_str_mv AT saklyhouneida braintumorradiogenomicclassificationofo6methylguaninednamethyltransferasepromotermethylationinmalignantgliomasbasedtransferlearning
AT saidmourad braintumorradiogenomicclassificationofo6methylguaninednamethyltransferasepromotermethylationinmalignantgliomasbasedtransferlearning
AT seekinsjayne braintumorradiogenomicclassificationofo6methylguaninednamethyltransferasepromotermethylationinmalignantgliomasbasedtransferlearning
AT guetariramzi braintumorradiogenomicclassificationofo6methylguaninednamethyltransferasepromotermethylationinmalignantgliomasbasedtransferlearning
AT kraiemnaoufel braintumorradiogenomicclassificationofo6methylguaninednamethyltransferasepromotermethylationinmalignantgliomasbasedtransferlearning
AT marzouguimehrez braintumorradiogenomicclassificationofo6methylguaninednamethyltransferasepromotermethylationinmalignantgliomasbasedtransferlearning